Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


[120-day follow-up after proximal femoral fractures-first results from the Geriatric Trauma Registry DGU®].

Schoeneberg C, Knobe M, Babst R, Friess T, Volland R, Hartwig E, Schmidt W, Lendemans S, Buecking B; AltersTraumaRegister DGU.

Unfallchirurg. 2019 Oct 9. doi: 10.1007/s00113-019-00730-4. [Epub ahead of print] German.


[Online survey for assessment of geriatric early rehabilitation complex treatment in geriatric trauma centers of the DGU by the medical services of the health funds].

Schoeneberg C, Friess T, Buecking B, Krinner S, Lendemans S, Schumacher J.

Unfallchirurg. 2019 Aug 26. doi: 10.1007/s00113-019-00715-3. [Epub ahead of print] German.


Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.

Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M.

PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019.


[Geriatric Trauma Center DGU®: Evaluation of clinical and economic parameters : A pilot study in a german university hospital].

Knobe M, Böttcher B, Coburn M, Friess T, Bollheimer LC, Heppner HJ, Werner CJ, Bach JP, Wollgarten M, Poßelt S, Bliemel C, Bücking B.

Unfallchirurg. 2019 Feb;122(2):134-146. doi: 10.1007/s00113-018-0502-y. German.


Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.

Herting F, Friess T, Umaña P, Middleton S, Klein C.

Leuk Lymphoma. 2018 Jun;59(6):1482-1485. doi: 10.1080/10428194.2017.1376740. Epub 2017 Sep 15. No abstract available.


[Results of the pilot phase of the Age Trauma Registry DGU®].

Bücking B, Hartwig E, Nienaber U, Krause U, Friess T, Liener U, Hevia M, Bliemel C, Knobe M; AltersTraumaRegister DGU.

Unfallchirurg. 2017 Jul;120(7):619-624. doi: 10.1007/s00113-017-0370-x. German.


Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model.

Maisel D, Birzele F, Voss E, Nopora A, Bader S, Friess T, Goller B, Laifenfeld D, Weigand S, Runza V.

PLoS One. 2016 Jul 27;11(7):e0159716. doi: 10.1371/journal.pone.0159716. eCollection 2016.


Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.

Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M.

J Hematol Oncol. 2016 Jun 28;9(1):50. doi: 10.1186/s13045-016-0280-3.


RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.


Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).

Herting F, Herter S, Friess T, Muth G, Bacac M, Sulcova J, Umana P, Dangl M, Klein C.

Eur J Haematol. 2016 Nov;97(5):461-470. doi: 10.1111/ejh.12756. Epub 2016 Apr 18.


XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.

Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, Weinzierl T, Rieder N, Bacac M, Ries CH, Kettenberger H, Schlothauer T, Friess T, Umana P, Klein C.

MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16.


Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.

Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS.

Clin Lung Cancer. 2016 Sep;17(5):375-383.e2. doi: 10.1016/j.cllc.2016.01.002. Epub 2016 Jan 22.


[Geriatric trauma centers from the idea to implementation. What has been achieved?].

Friess T, Hartwig E, Liener U, Sturm J, Hoffmann R.

Unfallchirurg. 2016 Jan;119(1):7-11. doi: 10.1007/s00113-015-0114-8. German.


Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA).

Bader S, Zajac M, Friess T, Ruge E, Rieder N, Gierke B, Heubach Y, Thomas M, Pawlak M.

Mol Cell Proteomics. 2015 Oct;14(10):2775-85. doi: 10.1074/mcp.O114.045542. Epub 2015 Jun 23.


[Interdisciplinary treatment in geriatric traumatology from the trauma surgeons' perspective : Results of a survey in Germany].

Bücking B, Walz M, Hartwig E, Friess T, Liener U, Knobe M, Ruchholtz S, Bliemel C.

Unfallchirurg. 2017 Jan;120(1):32-39. doi: 10.1007/s00113-015-0027-6. German.


Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B.

Cancer Chemother Pharmacol. 2015 Apr;75(4):837-50. doi: 10.1007/s00280-015-2697-8. Epub 2015 Feb 22.


[AltersTraumaZentrum DGU®].

Buecking B, Hoffmann R, Riem S, Sturm J, Schmucker U, Friess T, Liener U, Hartwig E.

Unfallchirurg. 2014 Sep;117(9):842-8. doi: 10.1007/s00113-014-2622-3. German.


Development of geriatric trauma centers -- an effort by the German Society for Trauma and Orthopaedics.

Pape HC, Friess T, Liener U, Ruchholtz S, Schmucker U, Sturm JA, Buecking G, Riem S, Hartwig E.

Injury. 2014 Oct;45(10):1513-5. doi: 10.1016/j.injury.2014.08.006. Epub 2014 Aug 8. No abstract available.


ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.

MAbs. 2014 Jul-Aug;6(4):1051-8. doi: 10.4161/mabs.29097. Epub 2014 May 7.


Value of the deep femoral artery as alternative inflow source in infrainguinal bypass surgery.

Dorweiler B, Friess T, Duenschede F, Doemland M, Espinola-Klein C, Vahl CF.

Ann Vasc Surg. 2014 Apr;28(3):633-9. doi: 10.1016/j.avsg.2013.04.026. Epub 2013 Dec 17.


Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.

Herting F, Friess T, Bader S, Muth G, Hölzlwimmer G, Rieder N, Umana P, Klein C.

Leuk Lymphoma. 2014 Sep;55(9):2151-5160. doi: 10.3109/10428194.2013.856008. Epub 2014 Feb 4.


Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.


RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner KP, Niederfellner G, Bossenmaier B.

Cancer Res. 2013 Aug 15;73(16):5183-94. doi: 10.1158/0008-5472.CAN-13-0099. Epub 2013 Jun 18.


Early orthogeriatric treatment of trauma in the elderly: a systematic review and metaanalysis.

Buecking B, Timmesfeld N, Riem S, Bliemel C, Hartwig E, Friess T, Liener U, Ruchholtz S, Eschbach D.

Dtsch Arztebl Int. 2013 Apr;110(15):255-62. doi: 10.3238/arztebl.2013.0255. Epub 2013 Apr 12. Review.


Endovascular treatment of symptomatic true-lumen collapse of the downstream aorta after open surgery for acute aortic dissection type A.

Conzelmann LO, Doemland M, Weigang E, Frieß T, Schotten S, Düber C, Vahl CF.

J Cardiovasc Surg (Torino). 2013 Apr;54(2):151-9. Review.


The heart as access to the aorta.

Weigang E, Weiler H, Frieß T, Vahl CF.

Eur J Cardiothorac Surg. 2013 Sep;44(3):559-61; discussion 561-2. doi: 10.1093/ejcts/ezt126. Epub 2013 Mar 20.


GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.


Targeting landing zone 0 by total arch rerouting and TEVAR: midterm results of a transcontinental registry.

Czerny M, Weigang E, Sodeck G, Schmidli J, Antona C, Gelpi G, Friess T, Klocker J, Szeto WY, Moeller P, Pochettino A, Bavaria JE.

Ann Thorac Surg. 2012 Jul;94(1):84-9. doi: 10.1016/j.athoracsur.2012.03.024. Epub 2012 May 16.


Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C.

Mol Cancer Ther. 2011 Jan;10(1):178-85. doi: 10.1158/1535-7163.MCT-10-0385.


Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P.

Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.


Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.


[Induction of antitumor immune response in the mouse model after vaccination with B7.1 expressing tumor cells].

Wollenberg B, Lang S, Friess T, Naujoks K, Mayer A, Kastenbauer E, Zeidler R.

Laryngorhinootologie. 1999 Jan;78(1):36-40. German.


[Clinic management: "continue on, Mr. Schmid!"].

Friess T.

Chirurg. 1998 Oct;69(10):suppl 319-20. German. No abstract available.


Human pancreatic tissue concentration of bactericidal antibiotics.

Büchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, Schlegel P, Friess T, Beger HG.

Gastroenterology. 1992 Dec;103(6):1902-8.


Supplemental Content

Loading ...
Support Center